AVI BioPharma — Investor and Analyst Breakfast Recording and Presentations

Transitioning an Antisense Pioneer into a Leading RNA–based Drug Discovery and Development Company

September 10, 2008

Dr. Leslie Hudson, President and CEO, AVI BioPharma
RNA–based drug discovery and development
Audio (MP3), Slides (PDF)

Professor Francesco Muntoni, Professor of Pediatric Neurology, Head of the Dubowitz Neuromuscular Centre, University College London Institute of Child Health, London, UK
Duchenne Muscular Dystrophy (DMD): The disease, its clinical management and future treatment
Audio Part 1 (MP3), Audio Part 2 (MP3), Slides (PDF)

Dr. Leslie Hudson
Clinical Trials of AVI–4658 and the commercial prospects for a DMD franchise
Audio (MP3), Slides (PDF)

Dr. Ryszard Kole, SVP of Discovery Research, AVI BioPharma
Directed alternative splicing mediated by novel oligomers with increased potency and bioavailability
Audio (MP3), Slides (PDF)

Benjamin D. Johnson, Engineering Manager, Global Therapeutics, a COOK Medical Company
Developing a breakthrough drug–eluting stent (DES) technology using the GTX platform and an improved application of antisense therapy: AVI–5126
Audio (MP3), Slides (PDF)

Dr. Patrick Iversen, SVP of Strategic Alliances, AVI BioPharma
Biodefense priorities for AVI and the enablement of HCV drug discovery
Audio Part 1 (MP3), Audio Part 2 (MP3), Slides (PDF)

J. David Boyle, SVP Finance and CFO, AVI BioPharma
Building an RNA–based drug discovery and development company
Audio (MP3), Slides (PDF)

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward–looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company’s Securities and Exchange Commission filings.